as informed in Those are the basic tenets of President Donald Trump’s plan to reduce prescription drug prices in the United States.
During the campaign, Trump also floated a plan to make it easier to import prescription drugs from other countries.
Other countries, including Canada, France, and the United Kingdom, allow government officials to negotiate drug prices.
“Foreign price controls reduce the resources of American drug companies to finance drug and R&D innovation.”After the meeting, The Campaign for Sustainable Rx Pricing (CSRxP) applauded the president’s focus on reducing drug prices.
Some experts say that has kept prescription prices down in those countries.
Sanders Open To Working With Trump To Lower Drug Prices
5453919Democratic socialist Vermont Sen. Bernie Sanders said Tuesday he is willing to work with President Donald Trump on lowering drug prices.
“The root of this problem is that we are the only major country not to negotiate drug prices with the pharmaceutical industry,” Sanders said.
Trump met with pharmaceutical executives Tuesday morning and told them, “we have to lower drug prices.”“I look forward to working with President Trump on this issue if he is serious about standing up to the pharmaceutical industry and reducing drug prices,” Sanders said in a statement Tuesday.
Trump, however, seemed to back away from his campaign rhetoric about negotiating drug prices and instead called for lowering taxes and regulations on the pharmaceutical market in order to lower the price of medicine.
After Trump withdrew the U.S. from the Trans-Pacific Partnership, Sanders said, “if President Trump is serious about a new policy to help American workers, then I would be delighted to work with him.”Sanders is drafting legislation with Maryland Democratic Rep. Elijah Cummings that would aim to lower drug prices by allowing Medicare to negotiate with drug manufactures for lower prices.
referring to During the meeting, Mr. Trump also told the executives that he was close to naming a candidate to lead the F.D.A.
Battered by public outrage over the rising costs of drugs in recent years, the drug industry has regarded Mr. Trump warily in recent weeks.
Advertisement Continue reading the main story“Yep, we’ll get it,” Mr. Trump replied.
Pharmaceutical and biotechnology stocks rallied after his election as investors bet that Mr. Trump would reduce corporate taxes and adopt more industry-friendly policies than his Democratic opponent, Hillary Clinton, who had made reducing drug prices a campaign issue.
But drug safety advocates criticized his comments, saying that eliminating agency regulations would mean rolling back consumer protections on products as diverse as drugs, cosmetics, food and dietary supplements.
about the details read more from here
This content may collect you by Jack Oliver